Bulk Pharmaceutical API Sources for desloratadine

Bulk Pharmaceutical API Sources for desloratadine

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		D3787
Molport		MolPort-000-883-875
Hangzhou APIChem Technology		AC-1279
AKos Consulting & Solutions		AKOS000280921
Vitas-M Laboratory		STK586537
Vitas-M Laboratory		BBL010777
Amadis Chemical		A19515

Global Bulk Active Pharmaceutical Ingredient (API) Landscape for Desloratadine

Last updated: February 19, 2026

This analysis identifies key global manufacturers and suppliers of desloratadine bulk API, examining their production capabilities, regulatory compliance, and market presence. The focus is on entities possessing the infrastructure and certifications to meet the demands of pharmaceutical companies for both generic and novel formulations.

What are the primary global sources for desloratadine API?

The global supply chain for desloratadine API is characterized by a concentration of manufacturers in Asia, particularly India and China, alongside established players in Europe. These suppliers vary in scale, technological advancement, and regulatory adherence, impacting lead times, pricing, and the assurance of quality for downstream pharmaceutical production.

Leading API Manufacturers and Suppliers

The following companies represent a significant portion of the global desloratadine API market, based on reported production volumes, established supply agreements, and regulatory filings.

• India:

  • Laurus Labs: A prominent Indian pharmaceutical company with substantial API manufacturing capacity. Laurus Labs is a significant producer of various APIs, including antihistamines. Their facilities adhere to GMP standards and have undergone inspections by major regulatory bodies.
  • Divi's Laboratories: Another major Indian API manufacturer known for its backward integration and large-scale production. Divi's Laboratories has a strong global footprint in API supply, including desloratadine.
  • Dr. Reddy's Laboratories: A diversified pharmaceutical company that manufactures and supplies a range of APIs. Dr. Reddy's has established manufacturing sites that comply with international quality standards.
  • Aurobindo Pharma: A significant player in both finished dosage forms and APIs. Aurobindo Pharma's API division is a key supplier globally, with desloratadine production being a part of their portfolio.
  • Granules India: Specializes in the production of APIs and pharmaceutical intermediates. Granules India has multiple manufacturing units with international regulatory approvals.

• China:

  • Zhejiang Huahai Pharmaceutical: A leading Chinese pharmaceutical manufacturer with extensive API production. Huahai has a strong focus on regulated markets, holding certifications from the FDA and EMA.
  • Hubei Biocause Pharmaceutical: A major producer of active pharmaceutical ingredients, including antihistamines. Biocause operates large-scale manufacturing facilities and exports to numerous countries.
  • Suzhou Pharma (part of Simcere Pharmaceutical Group): While primarily known for finished formulations, Simcere Pharmaceutical Group's API division, including Suzhou Pharma, is involved in the production of key APIs.
  • Anke Bio: A significant biotechnology and pharmaceutical company with API manufacturing capabilities. Anke Bio's product range includes intermediates and APIs for various therapeutic areas.

• Europe:

  • Teva Pharmaceutical Industries (Israel/Europe): While a global entity, Teva has significant API manufacturing operations within Europe. They are a major supplier of generic APIs and maintain high regulatory compliance.
  • CordenPharma: A contract development and manufacturing organization (CDMO) with European facilities that can produce APIs for clients. CordenPharma is known for its specialized manufacturing capabilities and regulatory expertise.

Comparative Production Capacity and Scale

Production capacity varies significantly among these suppliers. Companies like Divi's Laboratories and Laurus Labs are known for their multi-tonnage capacity, enabling them to fulfill large-scale supply contracts. Chinese manufacturers, such as Zhejiang Huahai Pharmaceutical, also operate at substantial scales. European manufacturers, while potentially smaller in sheer volume compared to Asian giants, often emphasize highly specialized production, stringent quality control, and direct access to regulated markets.

Manufacturer	Primary Region	Indicative Scale	Key Certifications
Laurus Labs	India	Large to Very Large	US FDA, EDQM, WHO GMP, PMDA (Japan)
Divi's Laboratories	India	Very Large	US FDA, EMA, PMDA (Japan), TGA (Australia)
Dr. Reddy's Laboratories	India	Large	US FDA, EMA, MHRA (UK)
Aurobindo Pharma	India	Large	US FDA, EMA, TGA (Australia)
Granules India	India	Medium to Large	US FDA, EDQM, COFEPRIS (Mexico)
Zhejiang Huahai Pharmaceutical	China	Large to Very Large	US FDA, EMA, PMDA (Japan), WHO GMP
Hubei Biocause Pharmaceutical	China	Large	SFDA (China), WHO GMP
Suzhou Pharma	China	Medium to Large	SFDA (China), WHO GMP
Anke Bio	China	Medium	SFDA (China)
Teva Pharmaceutical Industries	Europe	Large	US FDA, EMA, PMDA (Japan), TGA (Australia)
CordenPharma	Europe	Variable (CDMO)	US FDA, EMA, Swissmedic, PMDA (Japan)

Note: Indicative scale is an estimation based on public information and industry reports. Key Certifications are examples and not exhaustive.

What regulatory standards must desloratadine API suppliers meet?

Suppliers of desloratadine API must adhere to stringent international and national regulatory standards to ensure product quality, safety, and efficacy. Compliance is critical for market access, particularly in highly regulated regions like the United States, Europe, and Japan.

Good Manufacturing Practices (GMP)

All reputable desloratadine API manufacturers operate under Good Manufacturing Practices (GMP). These guidelines, established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), dictate the minimum requirements for facilities, equipment, personnel, and quality control systems.

• Key GMP Components:
  • Quality Management System (QMS): A comprehensive system encompassing organizational structure, procedures, processes, and resources to ensure quality.
  • Personnel: Requirements for training, hygiene, and qualifications of staff involved in API manufacturing.
  • Premises and Equipment: Standards for the design, construction, maintenance, and cleaning of manufacturing facilities and equipment to prevent contamination and mix-ups.
  • Documentation and Records: Detailed requirements for batch records, validation protocols, standard operating procedures (SOPs), and analytical test results.
  • Production and Process Controls: Procedures to ensure consistency and prevent deviations during the manufacturing process.
  • Packaging and Labeling: Controls to ensure proper identification and prevent mix-ups.
  • Storage and Distribution: Conditions to maintain API integrity during storage and transport.
  • Quality Control: Procedures for sampling, testing, and release of raw materials, intermediates, and finished APIs.

Regulatory Filings and Inspections

API manufacturers are subject to rigorous scrutiny through regulatory filings and inspections.

• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe and other regions) with regulatory authorities. These confidential documents contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies reference these filings in their own drug product applications.
  • US FDA DMF: A submission to the FDA providing detailed information about the manufacturing, processing, packaging, and storing of the drug substance.
  • EU ASMF: Similar to the US DMF, allowing regulatory authorities to review confidential manufacturing information.
• Inspections: Regulatory agencies conduct routine and ad-hoc inspections of manufacturing facilities to verify compliance with GMP and the information provided in DMFs/ASMFs. Successful inspection outcomes are crucial for market access.
  • FDA Inspections: Essential for APIs intended for the U.S. market.
  • EMA Inspections (or national competent authority inspections within the EU): Required for APIs used in medicines marketed in the European Union.
  • PMDA (Japan) Inspections: Necessary for APIs destined for the Japanese market.
  • Other National Authorities: Inspections by bodies like Health Canada, Australia's TGA, and Brazil's ANVISA are also important for specific regional markets.

Impurity Profiling and Control

A critical aspect of desloratadine API manufacturing is the control of impurities. Regulatory guidelines, such as ICH Q3A (Impurities in New Drug Substances) and ICH Q3B (Impurities in New Drug Products), set strict limits for identified, unidentified, and genotoxic impurities. Manufacturers must demonstrate a thorough understanding of their impurity profiles and implement validated analytical methods to ensure these are within acceptable limits.

• Key Impurity Considerations:
  • Process-Related Impurities: Byproducts formed during the synthesis of desloratadine.
  • Degradation Products: Impurities formed during storage due to decomposition.
  • Residual Solvents: Solvents used in the manufacturing process that remain in the API. ICH Q3C provides guidelines for acceptable levels.
  • Elemental Impurities: Contamination from catalysts or equipment. ICH Q3D provides risk-based guidance.
  • Genotoxic Impurities (GTIs): Impurities with the potential to damage DNA. Stringent control is required, often at parts-per-million (ppm) levels.

How does market demand and pricing influence desloratadine API sourcing?

Market demand for desloratadine, driven by the prevalence of allergic conditions and the availability of generic formulations, directly impacts API sourcing strategies and pricing. Fluctuations in demand, coupled with supply chain dynamics and raw material costs, create a complex pricing environment for pharmaceutical companies.

Demand Drivers

• Allergic Rhinitis and Urticaria Prevalence: Desloratadine is a widely prescribed second-generation antihistamine for the symptomatic relief of allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). The increasing incidence of these conditions globally fuels consistent demand.
• Generic Competition: The patent expiry of desloratadine's innovator drug has led to the widespread availability of generic versions. This has significantly increased the volume demand for desloratadine API as multiple generic manufacturers enter the market.
• New Formulations and Combinations: Development of new drug delivery systems or combination products incorporating desloratadine can create niche demand segments.
• Geographic Market Growth: Expansion of healthcare access and prescription rates in emerging markets contribute to overall demand growth.

Pricing Factors and Trends

The pricing of desloratadine API is influenced by several interconnected factors:

• Scale of Production: Manufacturers with large-scale, integrated production facilities can achieve lower per-unit costs through economies of scale. Indian and Chinese manufacturers often have a cost advantage in this regard.
• Raw Material Costs: The cost of key starting materials and reagents used in desloratadine synthesis directly affects the final API price. Volatility in commodity chemical markets can therefore influence API pricing.
• Regulatory Compliance Costs: Maintaining GMP compliance, conducting rigorous quality control, and managing regulatory filings represent significant operational costs that are factored into API pricing. Companies with established track records and approvals in multiple regulated markets may command higher prices due to reduced perceived risk for buyers.
• Competition: The presence of numerous API suppliers creates a competitive market. Intense competition, particularly from Asian manufacturers, tends to drive prices down, especially for high-volume generic APIs.
• Supply Chain Disruptions: Geopolitical events, natural disasters, or global health crises can disrupt supply chains, leading to temporary price increases due to shortages or increased logistical costs.
• Currency Exchange Rates: For international transactions, fluctuations in currency exchange rates can impact the effective price of desloratadine API.
• Contractual Agreements: Long-term supply agreements with pharmaceutical companies often involve negotiated pricing based on volume commitments and guaranteed supply, which can offer price stability.

Impact on Sourcing

Pharmaceutical companies seeking to source desloratadine API must balance cost-effectiveness with supply reliability and quality assurance.

• Cost-Driven Sourcing: Companies prioritizing cost may favor suppliers in India and China, where large-scale production and competitive labor markets often result in lower prices. However, this requires thorough due diligence regarding quality control and regulatory compliance.
• Quality and Reliability Driven Sourcing: Pharmaceutical companies with stringent quality requirements or those targeting highly regulated markets may opt for suppliers with established GMP certifications, a strong regulatory history, and a robust quality management system, even if it entails a higher price point. This often includes European suppliers or major Indian players with extensive international regulatory approvals.
• Risk Mitigation: Diversifying the supplier base across different geographies (e.g., sourcing from both India and Europe) can mitigate supply chain risks and provide leverage in price negotiations.

What are the technical considerations for sourcing desloratadine API?

Beyond regulatory and commercial aspects, technical considerations are paramount when selecting a desloratadine API supplier. These include the API's physical and chemical properties, the manufacturing process employed, and the analytical testing capabilities of the supplier.

Physical and Chemical Specifications

Desloratadine API must meet a defined set of physical and chemical specifications to ensure its suitability for formulation into finished dosage forms. These specifications are typically outlined in pharmacopoeias (e.g., USP, EP) and are part of the supplier's Certificate of Analysis (CoA).

• Chemical Name: 8-Chloro-6,11-dihydro-11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine.
• Molecular Formula: C19H19ClN2.
• Molecular Weight: 310.82 g/mol.
• Appearance: White to off-white crystalline powder.
• Solubility: Sparingly soluble in water, soluble in methanol and ethanol.
• Melting Point: Approximately 133-137 °C (may vary based on polymorphic form and purity).
• Polymorphism: Desloratadine can exist in different polymorphic forms, which can affect its dissolution rate, bioavailability, and manufacturing properties. Suppliers must control and characterize the polymorphic form supplied.
• Particle Size Distribution (PSD): For solid oral dosage forms, PSD is critical for dissolution, flowability, and compressibility. Suppliers may offer different PSD grades or provide milling services.
• Chiral Purity: Desloratadine does not possess a chiral center, simplifying purity requirements in this regard.

Manufacturing Process and Impurity Control

The synthetic route employed by the API manufacturer significantly influences the impurity profile and cost of production. Key aspects include:

• Synthetic Route: Common synthetic routes involve multi-step organic synthesis, often starting from precursors like loratadine or related intermediates. Manufacturers develop proprietary or licensed synthetic pathways.
• Process Validation: The entire manufacturing process, from raw material sourcing to final API isolation and purification, must be validated to ensure consistency and reproducibility.
• Control of Critical Process Parameters (CPPs): Parameters such as reaction temperature, pressure, pH, reaction time, and stirring speed must be precisely controlled and monitored.
• Impurity Profiling and Control: As discussed in the regulatory section, rigorous identification, characterization, and quantification of process-related impurities, degradation products, residual solvents, and elemental impurities are crucial. Suppliers must have validated analytical methods for these controls.

Analytical Testing and Quality Control

A robust quality control system by the API supplier is essential. This includes:

• Method Validation: All analytical methods used for testing API quality (e.g., HPLC for assay and impurities, GC for residual solvents, Karl Fischer for water content, ICP-MS for elemental impurities) must be validated according to ICH guidelines.
• Reference Standards: Availability of qualified reference standards for desloratadine and its known impurities is necessary for accurate testing.
• Stability Studies: Suppliers must conduct comprehensive stability studies under various temperature and humidity conditions (ICH Q1A) to establish retest periods or expiry dates and to monitor impurity formation over time.
• Certificate of Analysis (CoA): Each batch of desloratadine API supplied must be accompanied by a CoA detailing all test results against the approved specifications.

Packaging and Storage

Appropriate packaging and storage conditions are vital to maintain the quality and integrity of desloratadine API.

• Packaging Materials: Inert, protective packaging (e.g., double-lined polyethylene bags within fiber drums or suitable containers) that prevents moisture ingress, light exposure, and contamination.
• Storage Conditions: Typically stored in cool, dry conditions, protected from light, as specified by the manufacturer based on stability data.

Key Takeaways

• The global supply of desloratadine API is dominated by manufacturers in India and China, known for large-scale production and cost-effectiveness, alongside established European suppliers focusing on stringent quality and regulatory compliance.
• Adherence to Good Manufacturing Practices (GMP) and successful navigation of regulatory filings (DMFs/ASMFs) and inspections by bodies like the FDA and EMA are non-negotiable requirements for API suppliers.
• Market demand is driven by the prevalence of allergic conditions and generic competition, while pricing is influenced by production scale, raw material costs, competition, and regulatory overhead.
• Technical considerations include stringent control of physical/chemical specifications, understanding the synthetic process and its impurity profile, robust analytical testing, and appropriate packaging/storage.

Frequently Asked Questions

• What is the typical retest period for desloratadine API from major suppliers? Major suppliers typically offer a retest period of 2 to 5 years, contingent on the specific packaging and storage conditions and validated by their stability studies.

• How does the polymorphic form of desloratadine API affect its suitability for pharmaceutical formulation? Different polymorphic forms can exhibit varying solubility, dissolution rates, and thermodynamic stability, which directly impact a drug product's bioavailability, shelf-life, and manufacturability. Suppliers must control and specify the polymorphic form.

• What are the primary concerns regarding impurities in desloratadine API for regulated markets? The primary concerns involve controlling process-related impurities, degradation products, residual solvents, and especially genotoxic impurities, which are subject to very strict limits by regulatory agencies like the FDA and EMA.

• Are there significant differences in the quality standards between Indian, Chinese, and European desloratadine API manufacturers? While all reputable manufacturers must comply with GMP, European manufacturers often have a longer history of compliance with FDA and EMA standards, and may have more advanced quality systems. However, many leading Indian and Chinese manufacturers also meet and exceed these standards, backed by extensive international regulatory approvals.

• What is the typical lead time for an order of desloratadine API from a large-scale manufacturer? Lead times can range from 4 to 12 weeks, depending on the supplier's production schedule, current inventory levels, order volume, and any required custom testing or quality assurance processes.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP) Regulations. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Guideline Q3D: Guideline for Elemental Impurities. [5] United States Pharmacopeia Convention. (n.d.). United States Pharmacopeia (USP). [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). [7] Industry reports and company disclosures related to API manufacturing capabilities. (Specific reports not cited due to proprietary nature and dynamic market information).